提上来： 国内亲人得了恶性淋巴瘤。比较严重。做过化疗。家人很着急正在考虑这个药。不知道该不该试啊。 - Ghost99 -

Dr Sun 讲的挺对，机体状态恢复一下，做免疫治疗比较好。您的亲属，经过化疗 自体骨髓移植，又有病情发展，估计可能没达到或短暂缓解。很可能是难治一类的淋巴瘤。淋巴瘤基本有两大类， 何杰金（HL）和非何杰金（NHL）淋巴瘤，前者预后较好，后者中也有不少类型，其中一些类型比较难治，预后不好。不知道您亲属什么类型。PD-1或类似PD-1的抗体药物，在淋巴瘤里已开始临床试验。 其中Nivolumab 和 pembrolizumab效果还不太明确。另一种Pidilizumab疗效看起来挺好。如果经济条件允许您亲属可以试试，如 Dr.Sun讲的，机体状态得回复，下边的Pidilizumab治疗 也是在减少肿瘤负荷量前提下做的。

报告说：A phase II single-arm international study of pidilizumab in relapsed or refractory DLBCL or primary mediastinal B-cell lymphoma （弥漫大B细胞淋巴瘤 和 原发性纵隔B细胞淋巴瘤，这两类都不太好治疗） after autologous stem cell transplant was performed with the rationale that PD-1 blockade post-transplant would be effective due to low-volume disease and the potential for immune remodeling. The study included 66 patients. In the 35 patients with measurable disease, the overall response rate was 51%, with 34% achieving complete response and 37% achieving stable disease. Correlative studies demonstrated an increase in PD-L1-bearing circulating lymphocytes, apparent 24 h after pidilizumab treatment, and sustained until almost 16 weeks. Subsequently, the drug was evaluated in conjunction with rituximab in a phase II single-arm open label study of 29 eligible patients with relapsed, refractory follicular lymphoma. There were no highgrade treatment-related adverse events, and the overall response rate was 66%, with an impressive 52% complete response rate.

所有跟帖： 

• 谢谢堪诚！是大B细胞淋巴瘤。 -Ghost99- ♀ (0 bytes) () 05/14/2016 postreply 10:54:00

• 如果你国内亲戚愿意尝试替代疗法，我建议一种叫“色来布维B17”的西方替代疗法 -LucasY- ♂ (882 bytes) () 05/15/2016 postreply 05:05:29

• 哦谢谢！能提供更多的信息吗？ -Ghost99- ♀ (0 bytes) () 05/15/2016 postreply 06:06:12

• 简单的说就是 -LucasY- ♂ (574 bytes) () 05/15/2016 postreply 06:54:16

• 谢谢，我查查看。 -Ghost99- ♀ (0 bytes) () 05/15/2016 postreply 09:17:22

• 这里是中国大B弥漫淋巴瘤治疗指南。三和四里谈到何时适合试验性治疗。 -Diana-Sun- ♀ (371 bytes) () 05/15/2016 postreply 10:53:41